Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Mar 29, 2023 3:41pm
65 Views
Post# 35367638

RE:RE:RE:Nintedanib sales for 2022

RE:RE:RE:Nintedanib sales for 2022


PoF, are you able to keep track of the various Masters and PhD McMaster students that have worked or are working on the PGX project?

This is a Masters thesis by AARON IMRAN HAYAT and was published in August 2021.  A year later in August 2022, a press release announced the expansion of collaborative work with McMaster to develop a therapeutic/prophylatic for COVID 19 lung fibrosis. Was there a student working on the PGX inhalable therapeutic during this one year period from Aug 2021 to Aug 2022? Was it SAFAA NAIEL who as a PhD candidate will be presenting the lastest data at the ATS conference as result of her work from August 2022 to early this year, did she fill in the gap from Aug. 2021 onward?
<< Previous
Bullboard Posts
Next >>